|
Malignant neoplasm of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of MIR34a and MIR34b/c occurs frequently and concomitantly in breast and lung cancer, as well as in pulmonary diseases tissues, but not in breast normal tissues adjacent to tumor.
|
29916548 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo tumor targeting and therapy was investigated in an orthotopic lung cancer model by microCT, fluorescence imaging, and immunohistochemistry.<b>Results:</b> The singular nanoscale formulation, incorporating oncogene siKRAS, tumor-suppressor stimulating miR-34a, and cisplatin, has shown enhanced toxicity against lung cancer cell line, KP cell.
|
28912139 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we reveal that miR-34a is significantly downregulated in NSCLC tissues and cell lines, suggesting that miR-34a might function as a tumor suppressor in lung cancer.
|
28825720 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results demonstrate a previously unrecognized role for miR-34a in modulating IR-induced senescence in human NSCLC cells and suggest that pharmacological intervention of miR-34a expression may represent a new therapeutic strategy for improving the efficacy of lung cancer radiotherapy.
|
29050242 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis.
|
27836543 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway.
|
28389657 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genome-wide analysis of miRNAs in blood cell fractions highlighted miR-34a as most significantly up-regulated in CD3+ cells of lung cancer patients.
|
27144431 |
2016 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore new therapeutic options, we successfully encapsulated MicroRNA-34a (miR-34a), a potent endogenous tumor suppressor in NSCLC into S6 aptamer-conjugated dendrimer to form lung cancer-targeted gene delivery nanoparticles (PAM-Ap/pMiR-34a NPs).
|
26406332 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
|
23805317 |
2013 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we demonstrated that pretransfection of miR-34a could increase the sensitivity of both lung cancer cell lines to cisplatin (DDP), and this could be reverted by the miR-34a inhibitor.
|
23036084 |
2013 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression.
|
24019906 |
2013 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The therapeutic potential of microRNAs for preventing and treating lung cancer using the Kras(LSL-G12D/+);p53(LSL-R172H/+)mouse model suggests that miR-34 may be useful in sensitizing tumors to other conventional therapeutics.
|
23487440 |
2013 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression and provide a compelling rationale to develop miR-34a as a therapeutic agent in lung cancer patients.
|
22850877 |
2012 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therapeutic delivery was demonstrated using mimics of the tumor suppressors, microRNA-34a (miR-34a) and let-7, both of which are often down regulated or lost in lung cancer.
|
21427705 |
2011 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, miR-34 family has been shown to be part of the p53 pathway which is frequently involved in lung cancer, and the expression of miR-34 has been reported to be regulated by DNA methylation.
|
21383543 |
2011 |